AI-Generated Digital Twins in ALS: Improving Confidence in Early-Stage Clinical Trials

"Digital twins help us make the most of the data we're getting from here. In this open-label study, digital twins obviously provide us with built-in placebo controls for each participant…they have a lot of key advantages over propensity score matching or other natural history controls that allow us to have more confidence in the data we're taking out of that person-intraperson comparison."

‍

‍

‍

_{Erin Fleming, COO, ProJenX. Unlearn x ProJenX, ALS Drug Development Summit 2025, Boston, MA.}